X‑Chem further expands Collaboration with Bayer to Discover Novel Medicines
WALTHAM, Mass. β October 3rd, 2017 β X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics based on an industry leading DNA-encoded library containing over 120 billion small molecules, and Bayer have further expanded their drug discovery collaboration across multiple therapeutic areas and target classes. The latest agreement with Bayer extends their access to X-Chemβs DEXβ’ technology by including the synthesis of custom Bayer DNA-Encoded Libraries and expanding the number of potential programs. The collaboration is focused on the discovery of innovative small molecule leads for complex drug targets in areas of high unmet medical need.
Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition
X‑Chem Announces Licensing of Two Discovery Programs to AbbVie
Small molecule drug discovery specialist XChem, Inc. today announced that AbbVie has exercised options to license two discovery programs. Under the terms of the partiesβ 2016 multi-target research collaboration, AbbVie had an option to an exclusive license to the programs, each of which comprises multiple novel, cell-active modulators of two historically challenging targets in oncology and immunology.
X‑Chem Appoints Christelle Huguet, Ph.D. as Chief Scientific Officer
X-Chem, Inc. today announced the appointment of Christelle Huguet, Ph.D. as Chief Scientific Officer, along with an executive leadership appointment for Matthew Clark, Ph.D. as Senior Vice President, Chemistry.
Structural insight into allosteric modulation of protease-activated receptor 2
Target Classes
Diverse Discovery at an Exponential Pace X-Chemβs DNA-encoded library (DEL) technology and medicinal chemistry expertise take small molecule discovery to...